Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Work
Year: 2021
Type: article
Abstract: <h3>Importance</h3> Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death receptor 1 [PD-1... more
Source: JAMA
Institutions Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sichuan Cancer Hospital, Harbin Medical University +30 more
Cites: 26
Cited by: 488
Related to: 10
FWCI: 106.8
Citation percentile (by year/subfield): 100
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze